Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Deutsch

Showing results (101-110 of 351) with videos related to

Pageof 36
Sort By:
Cancer Treatment Reviews|May 27, 2011
Minimal residual disease in solid neoplasia: New frontier or red-herring?Pierre Mordant, Yohann Loriot, Benoît Lahon, et al.
Journal for Immunotherapy of Cancer|December 20, 2017
Anti-PD-1 Vasculitis of the central nervous system or radionecrosis?Roger Sun, Francois-Xavier Danlos, Samy Ammari, et al.
Anti-Cancer Drugs|May 24, 2013
The combination of the antiviral agent cidofovir and anti-EGFR antibody cetuximab exerts an antiproliferative effect on HPV-positive cervical cancer cell lines' in-vitro and in-vivo xenograftsMélanie Deberne, Antonin Levy, Michele Mondini, et al.
Molecular Cancer Therapeutics|February 4, 2010
Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combinationPierre Mordant, Yohann Loriot, Céline Leteur, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 19, 2013
Lung cancer stem cell: fancy conceptual model of tumor biology or cornerstone of a forthcoming therapeutic breakthrough?Tony Sourisseau, Khaled A Hassan, Ignacio Wistuba, et al.
Head & Neck|May 15, 2015
Toxicity of concomitant cetuximab and radiotherapy with or without initial taxane-based induction chemotherapy in locally advanced head and neck cancerAntonin Levy, Francesca De Felice, Sara Bellefqih, et al.
Cancer Biology & Therapy|September 14, 2006
Radiosensitizing effects of the prenyltransferase inhibitor AZD3409 against RAS mutated cell linesKeith A Cengel, Eric Deutsch, Trevor C Stephens, et al.
Frontiers in Oncology|December 14, 2020
Optimization of Patient Management During the COVID-19 Pandemic: Chest CT Scan and PCR as Gatekeepers of the Radiation Therapy WorkflowRoger Sun, Samy Ammari, Sophie Bockel, et al.
Cancer Letters|September 23, 2011
Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenograftsCyrus Chargari, Celine Leteur, Eric Angevin, et al.
Cancer Immunology Research|September 26, 2024
Deleting Trim33 in Myeloid Cells Improves the Efficiency of Radiotherapy through an IFNβ-Dependent Antitumor Immune ResponseAnaïs Assouvie, Marine Gerbé-de-Thoré, Claire Torres, et al.
Pageof 36

Showing results (101-110 of 351) with videos related to

Sort By:
Pageof 36
Cancer Treatment Reviews|May 27, 2011
Minimal residual disease in solid neoplasia: New frontier or red-herring?Pierre Mordant, Yohann Loriot, Benoît Lahon, et al.
Journal for Immunotherapy of Cancer|December 20, 2017
Anti-PD-1 Vasculitis of the central nervous system or radionecrosis?Roger Sun, Francois-Xavier Danlos, Samy Ammari, et al.
Anti-Cancer Drugs|May 24, 2013
The combination of the antiviral agent cidofovir and anti-EGFR antibody cetuximab exerts an antiproliferative effect on HPV-positive cervical cancer cell lines' in-vitro and in-vivo xenograftsMélanie Deberne, Antonin Levy, Michele Mondini, et al.
Molecular Cancer Therapeutics|February 4, 2010
Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combinationPierre Mordant, Yohann Loriot, Céline Leteur, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 19, 2013
Lung cancer stem cell: fancy conceptual model of tumor biology or cornerstone of a forthcoming therapeutic breakthrough?Tony Sourisseau, Khaled A Hassan, Ignacio Wistuba, et al.
Head & Neck|May 15, 2015
Toxicity of concomitant cetuximab and radiotherapy with or without initial taxane-based induction chemotherapy in locally advanced head and neck cancerAntonin Levy, Francesca De Felice, Sara Bellefqih, et al.
Cancer Biology & Therapy|September 14, 2006
Radiosensitizing effects of the prenyltransferase inhibitor AZD3409 against RAS mutated cell linesKeith A Cengel, Eric Deutsch, Trevor C Stephens, et al.
Frontiers in Oncology|December 14, 2020
Optimization of Patient Management During the COVID-19 Pandemic: Chest CT Scan and PCR as Gatekeepers of the Radiation Therapy WorkflowRoger Sun, Samy Ammari, Sophie Bockel, et al.
Cancer Letters|September 23, 2011
Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenograftsCyrus Chargari, Celine Leteur, Eric Angevin, et al.
Cancer Immunology Research|September 26, 2024
Deleting Trim33 in Myeloid Cells Improves the Efficiency of Radiotherapy through an IFNβ-Dependent Antitumor Immune ResponseAnaïs Assouvie, Marine Gerbé-de-Thoré, Claire Torres, et al.
Pageof 36